Tango Therapeutics, Inc. Capital Expenditures
Tango Therapeutics, Inc. (TNGX) reported Capital Expenditures of -$22.00 thousand for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-11.
Financial Statements › Cash Flow › Investing Activities
us-gaap:PaymentsToAcquirePropertyPlantAndEquipment · last filed 2026-08-11
- Tango Therapeutics, Inc. payments to acquire property, plant, and equipment for the quarter ending 2026-06-30 was -$20.00K, a 103.21% decline year-over-year.
- Tango Therapeutics, Inc. payments to acquire property, plant, and equipment for the quarter ending 2026-03-31 was -$2.00K, a 103.92% decline year-over-year.
- Tango Therapeutics, Inc. payments to acquire property, plant, and equipment for the quarter ending 2025-12-31 was $222.00K, a 79.03% increase year-over-year.
- Tango Therapeutics, Inc. payments to acquire property, plant, and equipment for the quarter ending 2025-09-30 was $151.00K, a 31.30% increase year-over-year.
- Tango Therapeutics, Inc. payments to acquire property, plant, and equipment for fiscal 2025 was $1.05M, a 38.99% increase from fiscal 2024.
- Tango Therapeutics, Inc. payments to acquire property, plant, and equipment for fiscal 2024 was $754.00K, a 50.59% decline from fiscal 2023.
- Tango Therapeutics, Inc. payments to acquire property, plant, and equipment for fiscal 2023 was $1.53M, a 80.16% decline from fiscal 2022.
- Tango Therapeutics, Inc. payments to acquire property, plant, and equipment for fiscal 2022 was $7.69M, a 318.73% increase from fiscal 2021.
| Period end | Payments to Acquire Property, Plant, and Equipment 3 month | Payments to Acquire Property, Plant, and Equipment 6 month | Payments to Acquire Property, Plant, and Equipment 9 month | Payments to Acquire Property, Plant, and Equipment 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$20.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-11 | -$22.00K 10-Q · filed 2026-08-11 | $200.00K derived: sum of 3 quarters · filed 2026-08-11 | $351.00K derived: sum of 4 quarters · filed 2026-08-11 |
| 2026-03-31 | -$2.00K 10-Q · filed 2026-05-13 | $220.00K derived: sum of 2 quarters · filed 2026-05-13 | $371.00K derived: sum of 3 quarters · filed 2026-05-13 | $995.00K derived: sum of 4 quarters · filed 2026-08-11 |
| 2025-12-31 | $222.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-05 | $373.00K derived: sum of 2 quarters · filed 2026-03-05 | $997.00K derived: sum of 3 quarters · filed 2026-08-11 | $1.05M 10-K · filed 2026-03-05 |
| 2025-09-30 | $151.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-04 | $775.00K derived: sum of 2 quarters · filed 2026-08-11 | $826.00K 10-Q · filed 2025-11-04 | $950.00K derived: sum of 4 quarters · filed 2026-08-11 |
| 2025-06-30 | $624.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-11 | $675.00K 10-Q · filed 2026-08-11 | $799.00K derived: sum of 3 quarters · filed 2026-08-11 | $914.00K derived: sum of 4 quarters · filed 2026-08-11 |
| 2025-03-31 | $51.00K 10-Q · filed 2026-05-13 | $175.00K derived: sum of 2 quarters · filed 2026-05-13 | $290.00K derived: sum of 3 quarters · filed 2026-05-13 | $610.00K derived: sum of 4 quarters · filed 2026-05-13 |
| 2024-12-31 | $124.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-05 | $239.00K derived: sum of 2 quarters · filed 2026-03-05 | $559.00K derived: sum of 3 quarters · filed 2026-03-05 | $754.00K 10-K · filed 2026-03-05 |
| 2024-09-30 | $115.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-04 | $435.00K derived: sum of 2 quarters · filed 2025-11-04 | $630.00K 10-Q · filed 2025-11-04 | $856.00K derived: sum of 4 quarters · filed 2026-03-05 |
| 2024-06-30 | $320.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-05 | $515.00K 10-Q · filed 2025-08-05 | $741.00K derived: sum of 3 quarters · filed 2026-03-05 | $757.00K derived: sum of 4 quarters · filed 2026-03-05 |
| 2024-03-31 | $195.00K 10-Q · filed 2025-05-12 | $421.00K derived: sum of 2 quarters · filed 2026-03-05 | $437.00K derived: sum of 3 quarters · filed 2026-03-05 | $1.10M derived: sum of 4 quarters · filed 2026-03-05 |
| 2023-12-31 | $226.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-05 | $242.00K derived: sum of 2 quarters · filed 2026-03-05 | $906.00K derived: sum of 3 quarters · filed 2026-03-05 | $1.53M 10-K · filed 2026-03-05 |
| 2023-09-30 | $16.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-06 | $680.00K derived: sum of 2 quarters · filed 2024-11-06 | $1.30M 10-Q · filed 2024-11-06 | $2.34M derived: sum of 4 quarters · filed 2025-02-27 |
| 2023-06-30 | $664.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-07 | $1.28M 10-Q · filed 2024-08-07 | $2.33M derived: sum of 3 quarters · filed 2025-02-27 | $5.60M derived: sum of 4 quarters · filed 2025-02-27 |
| 2023-03-31 | $620.00K 10-Q · filed 2024-05-08 | $1.66M derived: sum of 2 quarters · filed 2025-02-27 | $4.94M derived: sum of 3 quarters · filed 2025-02-27 | $6.75M derived: sum of 4 quarters · filed 2025-02-27 |
| 2022-12-31 | $1.04M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-27 | $4.32M derived: sum of 2 quarters · filed 2025-02-27 | $6.13M derived: sum of 3 quarters · filed 2025-02-27 | $7.69M 10-K · filed 2025-02-27 |
| 2022-09-30 | $3.28M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-08 | $5.09M derived: sum of 2 quarters · filed 2023-11-08 | $6.65M 10-Q · filed 2023-11-08 | $7.35M derived: sum of 4 quarters · filed 2023-11-08 |
| 2022-06-30 | $1.81M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-07 | $3.37M 10-Q · filed 2023-08-07 | $4.07M derived: sum of 3 quarters · filed 2023-08-07 | $4.84M derived: sum of 4 quarters · filed 2023-08-07 |
| 2022-03-31 | $1.56M 10-Q · filed 2023-05-09 | $2.26M derived: sum of 2 quarters · filed 2023-05-09 | $3.03M derived: sum of 3 quarters · filed 2023-05-09 | $3.23M derived: sum of 4 quarters · filed 2023-05-09 |
| 2021-12-31 | $696.00K derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-27 | $1.47M derived: sum of 2 quarters · filed 2023-03-27 | $1.67M derived: sum of 3 quarters · filed 2023-03-27 | $1.84M 10-K · filed 2023-03-27 |
| 2021-09-30 | $774.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-10 | $976.00K derived: sum of 2 quarters · filed 2022-11-10 | $1.14M 10-Q · filed 2022-11-10 | $1.60M derived: sum of 4 quarters · filed 2022-11-10 |
| 2021-06-30 | $202.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-10 | $367.00K 10-Q · filed 2022-08-10 | $823.00K derived: sum of 3 quarters · filed 2022-08-10 | |
| 2021-03-31 | $165.00K 10-Q · filed 2022-05-11 | $621.00K derived: sum of 2 quarters · filed 2022-05-11 | ||
| 2020-12-31 | $456.00K derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-28 | $1.11M 10-K · filed 2022-03-28 | ||
| 2020-09-30 | $650.00K 10-Q · filed 2021-11-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Indivior Pharmaceuticals, Inc. (INDV) | $4.250B | 14.09 | |
| Viking Therapeutics, Inc. (VKTX) | United States | $4.287B | -8.51 |
| AbCellera Biologics Inc. (ABCL) | $3.879B | -14.59 | |
| Edgewise Therapeutics, Inc. (EWTX) | United States | $4.470B | -22.23 |
| ACADIA PHARMACEUTICALS INC (ACAD) | United States | $3.823B | 11.45 |
| Xenon Pharmaceuticals Inc. (XENE) | $3.684B | -14.27 | |
| Organon & Co. (OGN) | United States | $3.603B | 17.03 |
| IDEAYA Biosciences, Inc. (IDYA) | United States | $3.540B | -20.52 |
| Veradermics, Inc (MANE) | United States | $4.839B | |
| Amylyx Pharmaceuticals, Inc. (AMLX) | United States | $3.361B | -13.15 |